BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amet S, Launay-Vacher V, Clément O, Frances C, Tricotel A, Stengel B, Gauvrit JY, Grenier N, Reinhardt G, Janus N, Choukroun G, Laville M, Deray G. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study. Invest Radiol 2014;49:109-15. [PMID: 24169070 DOI: 10.1097/RLI.0000000000000000] [Cited by in Crossref: 53] [Cited by in F6Publishing: 10] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:223-30. [PMID: 31816007 DOI: 10.1001/jamainternmed.2019.5284] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 62.0] [Reference Citation Analysis]
2 Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015;50:416-22. [PMID: 25756684 DOI: 10.1097/RLI.0000000000000145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 7.8] [Reference Citation Analysis]
3 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
4 Barbieri S, Schroeder C, Froehlich JM, Pasch A, Thoeny HC. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. Contrast Media Mol Imaging 2016;11:245-50. [PMID: 26929131 DOI: 10.1002/cmmi.1683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
5 Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017;45:988-997. [PMID: 27726239 DOI: 10.1002/jmri.25486] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
6 Vandesquille M, Li T, Po C, Ganneau C, Lenormand P, Dudeffant C, Czech C, Grueninger F, Duyckaerts C, Delatour B, Dhenain M, Lafaye P, Bay S. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease. MAbs 2017;9:1016-27. [PMID: 28657418 DOI: 10.1080/19420862.2017.1342914] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
7 Michaely HJ, Aschauer M, Deutschmann H, Bongartz G, Gutberlet M, Woitek R, Ertl-Wagner B, Kucharczyk W, Hammerstingl R, De Cobelli F, Rosenberg M, Balzer T, Endrikat J. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Invest Radiol 2017;52:55-60. [PMID: 27529464 DOI: 10.1097/RLI.0000000000000307] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
8 Ranga A, Agarwal Y, Garg KJ. Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function. Indian J Radiol Imaging 2017;27:141-7. [PMID: 28744073 DOI: 10.4103/0971-3026.209212] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 29.0] [Reference Citation Analysis]
9 Zhang B, Liang L, Chen W, Liang C, Zhang S. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. PLoS One 2015;10:e0129720. [PMID: 26076348 DOI: 10.1371/journal.pone.0129720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
10 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]